NCT01533740已完成不适用
Observational Study of the Impact of Circulating T Regulatory Cells (Tregs) on Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated With Standard Fluorouracil/Irinotecan/Bevacizumab First Line Therapy
University of Rome Tor Vergata1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2012年3月最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Impact of Tregs frequency on overall survival
研究概览
简要总结
Aim of the present study is to investigate whether baseline or early post-treatment (one month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs OR CD4+/CD25high/FOXP3+ T cells), known to suppress antitumor immune response, may influence long-term clinical outcome (i.e. radiological response, progression-free survival or overall survival) in metastatic colorectal cancer patients treated with a standard first-line chemotherapy including fluorouracil, irinotecan and bevacizumab
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with histologically or cytologically confirmed diagnosis of metastatic colorectal cancer not amenable to surgery
- •Adjuvant treatment ended ≥6 months before the study entry
- •No prior exposure to irinotecan and/or bevacizumab in the adjuvant treatment
- •No prior exposure to cytotoxic drugs for the metastatic disease
- •At least one measurable lesion according to the RECIST criteria
- •adequate laboratory parameters (Hemoglobin level ≥ 9.0 g/dL; Neutrophil count > 1.5 x 109/L; Platelets count >100 x 109/L; Total bilirubin <1.5 time the upper-normal limits (UNL) and ASAT (SGOT) and/or ALAT (SGPT) <2.5 x UNL, or <5 x UNL in case of liver metastases; alkaline phosphatase <2.5 x UNL, or <5 x UNL in case of liver metastases; PT-INR/PTT < 1.5 x UNL;Creatinine clearance > 50 mL/min or serum creatinine <1.5 x UNL; Urine dipstick of proteinuria < 2+)
- •Written informed consent.
- •Patients must be accessible for treatment and follow up.
排除标准
- •Untreated brain metastases or spinal cord compression
- •History of inflammatory bowel disease and/or acute or subacute bowel occlusion.
- •Serious, non-healing wound, ulcer, or bone fracture
- •Evidence of bleeding diathesis or coagulopathy.
- •Uncontrolled hypertension.
- •Clinically significant cardiovascular disease(cerebrovascular accidents ≤ 6 months, myocardial infarction ≤ 6 months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication)
- •Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes.
- •Chronic, daily treatment with high-dose aspirin (>325 mg/day) or other medications known to predispose to gastrointestinal ulceration.
- •Treatment with any investigational drug within 30 days prior to enrolment.
- •Patients with known allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications
- •Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal and squamous cell carcinoma or cervical cancer in situ
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.
- •Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline
- •Substance abuse, medical, psychological or social conditions that may interfere with the participation into the study or the evaluation of study results
- •Patients unable to swallow oral medications
结局指标
主要结局
Impact of Tregs frequency on overall survival
时间窗: 12 months
次要结局
- Impact of Tregs frequency progression free survival(12 months)
- Impact of Tregs frequency radiologic response rate(6 months)
研究者
Vincenzo Formica
MD, PhD
University of Rome Tor Vergata
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung CancerCirculating Tumor CellsNCT01052818National Institute of Cancerología200
进行中（未招募）
不适用
Childhood Migraine Treatment Noninvasive Pulsed Radiofrequency vs FlunarizineMigraine DiseaseNCT06753825Damla Yürük60
已完成
不适用
Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal CancerCirculating Tumor CellsColorectal CancerGastric CancerNCT02955173Qilu Hospital of Shandong University467
招募中
不适用
Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With LymphomasHemophagocytic LymphohistiocytosesLymphomaNCT06585124Fondazione Policlinico Universitario Agostino Gemelli IRCCS150
Unknown
3 期
Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment OutcomeCervix CancerNCT00348738Medical University of Vienna300